UNH241227C515000
- 0.06
- -1.54-96.25%
UnitedHealth Newsroom
Raymond James Maintains UnitedHealth(UNH.US) With Buy Rating
Barclays Maintains UnitedHealth(UNH.US) With Buy Rating, Maintains Target Price $655
Analysts Conflicted on These Healthcare Names: Ionis Pharmaceuticals (IONS) and UnitedHealth (UNH)
Bernstein Maintains UnitedHealth(UNH.US) With Buy Rating, Maintains Target Price $658
Morgan Stanley Maintains UnitedHealth(UNH.US) With Buy Rating, Maintains Target Price $610
Morgan Stanley Sticks to Its Buy Rating for UnitedHealth (UNH)
Bernstein Maintains UnitedHealth(UNH.US) With Buy Rating, Maintains Target Price $658
Bernstein Reaffirms Their Buy Rating on UnitedHealth (UNH)
Bernstein Maintains UnitedHealth(UNH.US) With Buy Rating, Maintains Target Price $658
Analysts Offer Insights on Healthcare Companies: Syndax Pharmaceuticals (SNDX), UnitedHealth (UNH) and Disc Medicine (IRON)
Jefferies Maintains UnitedHealth(UNH.US) With Buy Rating, Cuts Target Price to $635
UnitedHealth Price Target Raised to $640.00/Share From $610.00 by Oppenheimer
UnitedHealth Is Maintained at Outperform by Oppenheimer
Cantor Fitzgerald Adjusts Price Target on UnitedHealth Group to $700 From $644
Oppenheimer Maintains UnitedHealth(UNH.US) With Buy Rating, Raises Target Price to $640
A Quick Look at Today's Ratings for UnitedHealth(UNH.US), With a Forecast Between $655 to $715
UnitedHealth (UNH) Gets a Buy From Oppenheimer
Positive Growth Trajectory and Robust Financial Health Reinforce Buy Rating for UnitedHealth
George Hill's Buy Rating on UnitedHealth Driven by Investor Conference Insights and Optimistic 2025 Revenue Projections
Argus Adjusts Price Target on UnitedHealth Group to $670 From $600